PMID: 7537608Jan 1, 1994Paper

Characterization of peripheral blood progenitor cells mobilized by cytotoxic chemotherapy and recombinant human granulocyte colony-stimulating factor

Journal of Hematotherapy
R HaasW Hunstein

Abstract

The purpose of this study was to evaluate the antigenic profile of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPC) in patients with non-Hodgkin's lymphoma (NHL), Hodgkin's disease (HD), and multiple myeloma (MM). The mobilization regimens consisted of high-dose cytarabine/mitoxantrone for patients with NHL, DexaBEAM for patients with HD, and high-dose cyclophosphamide (4 or 7 g per m2) for patients with MM. Cytotoxic therapy was supported by recombinant human G-CSF (Filgrastim, 300 micrograms/day sc) to shorten the period of neutropenia and to increase the number of circulating hematopoietic progenitor cells. The mean numbers of circulating CD34+ cells/microliters during leukocyte recovery were different between patient groups, 80.5 +/- 9.8 (mean +/- SEM) in low-grade NHL and 51.2 +/- 9.7 in high-grade NHL compared with 31.3 +/- 6.9 in HD and 24.4 +/- 4.1 in patients with MM. As a result, the greatest numbers of CD34+ cells/kg collected per leukapheresis were observed in patients with NHL, whereas the collection efficiency was substantially lower in patients with HD or MM. Patients with MM had also the smallest proportion of CD34+ cells in the mononuclear cell fraction (mean 0.79...Continue Reading

Citations

Jan 22, 2004·Archives of Medical Research·Héctor MayaniPatricia Flores-Guzmán
Sep 25, 2002·Critical Reviews in Oncology/hematology·Louis M PelusAndrew G King
Apr 29, 1999·Transfusion·A G SmolowiczU Tidefelt
Jul 29, 2010·EMBO Molecular Medicine·Emanuela Anna RoselliGiuliana Ferrari
Oct 1, 1995·Current Opinion in Immunology·M Theobald
Oct 1, 1995·Current Opinion in Immunology·Y Reisner, H Segall
Oct 6, 1999·Current Opinion in Immunology·E W PetersdorfJ A Hansen
Mar 16, 2005·Current Opinion in Immunology·Loredana RuggeriAndrea Velardi
Sep 28, 2002·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Franco Aversa
Jan 19, 2002·Seminars in Hematology·Massimo F MartelliYair Reisner
Sep 30, 2000·Stem Cells·M Körbling
Sep 30, 2000·Stem Cells·L KanzS Scheding
Feb 16, 2011·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Ines BojanicBoris Labar
Aug 1, 1996·Journal of Hematotherapy·P DregerN Schmitz
Dec 1, 1995·Stem Cells·W I BensingerC D Buckner
Mar 31, 2021·Der Internist·Hartmut Goldschmidt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.